Why Is Syndax Pharmaceuticals (SNDX) Stock Down 17.34% Today?
Key Takeaways
- SNDX shares are down roughly 17.34% in today's session, trading near $13.68 after closing at $16.55 in the prior session.
- The primary catalyst is a clinical setback: the Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis (IPF) missed its primary endpoint.
- The company has decided to discontinue further development of axatilimab in IPF, a meaningful blow to pipeline optionality.
- Wall Street analysts largely defended the stock, noting IPF was never a core component of their valuation models.
- Traders are now focused on the company's commercial franchises — Revuforj and Niktimvo — and upcoming label-expansion data.
Opening Summary
Syndax Pharmaceuticals, Inc. (SNDX), a commercial-stage biopharmaceutical company developing therapies for cancer and rare diseases, is under heavy selling pressure today. The stock is down approximately 17.34%, changing hands near $13.68 versus a prior-session close of $16.55. The selloff extends the decline that began in after-hours trading after the company disclosed that its investigational drug axatilimab failed to hit the primary goal of a mid-stage study in idiopathic pulmonary fibrosis, a progressive and often fatal lung-scarring disease. The company's decision to halt further IPF development for the drug has sharpened investor focus on its core oncology and graft-versus-host disease (GVHD) franchises.
Trial Setback: Axatilimab Misses in IPF
The driving force behind today's decline is a disappointing clinical readout. Syndax's 26-week MAXPIRe Phase 2 study, which enrolled roughly 145 patients across dozens of sites, tested axatilimab against placebo in idiopathic pulmonary fibrosis. The trial's primary measure — the annualized rate of decline in forced vital capacity, a key marker of lung function — failed to show a benefit for the drug over placebo. Secondary measures, including time to disease progression and quality-of-life scores, also showed no evidence of benefit.
While the safety profile remained largely consistent with prior studies and no new safety signals emerged, the efficacy miss effectively ends the company's ambitions for axatilimab in IPF. Syndax said it would not advance the drug further in this indication. Because IPF represented a meaningful expansion opportunity for a drug already commercialized as Niktimvo, the market reaction has been sharply negative.
Analysts Defend the Core Thesis
Despite the sharp move lower, several analysts moved to reassure investors. Multiple firms reiterated Buy ratings, arguing that IPF was never a central part of their valuation frameworks and was instead treated as "upside optionality." Analysts emphasized that the trial failure does not affect axatilimab's approved use in chronic graft-versus-host disease, nor does it alter ongoing trials of the drug in earlier lines of GVHD treatment. The message to investors was that the company's underlying fundamentals — anchored by its two commercial assets, Revuforj (revumenib) and Niktimvo (axatilimab-csfr) — remain intact even as near-term pipeline optionality has narrowed.
Broader Market Context and Trading Activity
The move reflects a stock-specific catalyst rather than broad sector pressure, though the biotech space has been volatile. Notably, the Syndax announcement came on the same day that Bristol Myers Squibb reported mixed late-stage results for its own IPF candidate, underscoring how difficult the IPF indication has been for drug developers and amplifying investor caution around the therapeutic area. For SNDX, trading volume has been elevated relative to its average, consistent with heavy repositioning as investors digest the trial readout. Technically, the stock has broken decisively below its 50-day moving average and is now trading well beneath levels that had provided support earlier in the year, reflecting a sustained multi-month downtrend.
What Comes Next for SNDX
Looking ahead, investor attention shifts back to the commercial execution of Revuforj and Niktimvo and the company's efforts to move both assets into earlier lines of treatment. Syndax is also testing axatilimab in frontline GVHD, with additional data expected over the coming quarters. The next scheduled catalyst is the company's third-quarter earnings report, currently estimated for early November, which will provide a clearer read on revenue trajectory and spending discipline. Key risks include whether the two commercial products can scale quickly enough to absorb the company's substantial research and operating expenses, as well as the possibility that some investors reassess pipeline value in the wake of the IPF setback. As with all clinical-stage and newly commercial biotechs, future readouts and label-expansion decisions remain the primary swing factors.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots that have demonstrated the strongest performance under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and traded symbols. Only the strongest performers are featured in this section, making it a useful starting point for traders seeking systematic, data-driven approaches. Explore the Trending AI Robots page to discover which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
SNDX's RSI Indicator entering oversold zone
The RSI Oscillator for SNDX moved into overbought territory on October 13, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNDX advanced for three days, in 223 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
SNDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNDX as a result. In 75 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for SNDX turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 33 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Aroon Indicator for SNDX entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. SNDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (105.263) is normal, around the industry mean (26.782). P/E Ratio (117.647) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (6.010) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biopharmaceuticals for novel cancer therapies
Industry Biotechnology
Advertisement